Patents by Inventor Thomas J. Borody
Thomas J. Borody has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10463702Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: GrantFiled: June 6, 2019Date of Patent: November 5, 2019Assignee: Crestovo Holdings LLCInventor: Thomas J. Borody
-
Publication number: 20190328825Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: July 12, 2019Publication date: October 31, 2019Applicants: Arizona Board of Regents on behalf of Arizona State University, Regents of the University of Minnesota, Crestovo Holdings LLCInventors: James ADAMS, Rosa KRAJMALNIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Publication number: 20190290704Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: ApplicationFiled: June 12, 2019Publication date: September 26, 2019Applicant: CRESTOVO HOLDINGS LLCInventor: Thomas J. BORODY
-
Publication number: 20190282631Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: ApplicationFiled: June 6, 2019Publication date: September 19, 2019Applicant: CRESTOVO HOLDINGS LLCInventor: Thomas J. BORODY
-
Publication number: 20190216860Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.Type: ApplicationFiled: March 25, 2019Publication date: July 18, 2019Applicant: CRESTOVO HOLDINGS LLCInventor: Thomas J. BORODY
-
Publication number: 20190175665Abstract: The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.Type: ApplicationFiled: December 6, 2018Publication date: June 13, 2019Inventor: Thomas J. BORODY
-
Publication number: 20190134106Abstract: This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including storage, including long term storage, at ambient temperature. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disordor, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.Type: ApplicationFiled: November 5, 2018Publication date: May 9, 2019Applicant: CRESTOVO HOLDINGS LLCInventor: Thomas J. BORODY
-
Publication number: 20190134144Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: December 28, 2018Publication date: May 9, 2019Applicants: Arizona Board Regents on behalf of Arizona State University, Regents of the University of Minnesota, Crestovo Holdings LLCInventors: James ADAMS, Rosa KRAJMALNIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Publication number: 20190083518Abstract: Disclosed are compositions and methods for treating, amelioriating, reversing and/or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and/or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof.Type: ApplicationFiled: September 20, 2018Publication date: March 21, 2019Inventors: Thomas J. Borody, Debra A. Peattie
-
Publication number: 20170348360Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. This application provides novel compositions and methods for treating various disorders or conditions that are associated with a dysfunctional intestinal microbiota. In particular, this application provides compositions and methods that can treat or cure gastrointestinal (GI) disorders such as Inflammatory Bowel Disease (IBD), including, for example, Crohn's Disease and ulcerative colitis.Type: ApplicationFiled: June 1, 2017Publication date: December 7, 2017Inventor: Thomas J. BORODY
-
Publication number: 20160339065Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: May 23, 2016Publication date: November 24, 2016Applicants: Arizona Board of Regents on Behalf of Arizona State University, Regents of the University of Minnesota, Crestovo LLCInventors: James ADAMS, Rosa KRAJMALIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Patent number: 7776850Abstract: The present invention provides methods for the treatment of respiratory tract mucositis in individuals in need of such treatment, the method comprising the systemic administration to the individual of therapeutically effective amounts of at least one anti-fungal agent and at least one anti-bacterial agent, wherein the treatment does not involve the cessation of use of emollients by the individual. The present invention also provides compositions suitable for use in the treatment of respiratory tract mucositis.Type: GrantFiled: July 9, 2007Date of Patent: August 17, 2010Assignee: Atopic Pty, Ltd.Inventor: Thomas J. Borody
-
Patent number: 7624736Abstract: An endoscopic mouthguard comprising a bite block comprising a generally annular body adapted to be inserted into the mouth of a patient so as to maintain the upper and lower teeth of the patient in a spaced apart relationship and define an endoscopic passage for introduction of an endoscope into the oral cavity of the patient. The bite block includes a gas delivery passage for delivery of a gas to the oral cavity of the patient, and a gas distribution manifold detachably engaged with the bite block. The gas distribution manifold comprises at least one inlet port for receiving gas from a gas supply, at least one nasal outlet port in fluid communication with the inlet port and adapted so as to direct gas to or toward the nasal passages of the patient; and an oral outlet port in fluid communication with the inlet port.Type: GrantFiled: August 9, 2004Date of Patent: December 1, 2009Inventor: Thomas J. Borody
-
Patent number: 7241741Abstract: The present invention provides methods for the treatment of respiratory tract mucositis in individuals in need of such treatment, the method comprising the systemic administration to the individual of therapeutically effective amounts of at least one anti-fungal agent and at least one anti-bacterial agent, wherein the treatment does not involve the cessation of use of emollients by the individual. The present invention also provides compositions suitable for use in the treatment of respiratory tract mucositis.Type: GrantFiled: July 23, 2004Date of Patent: July 10, 2007Assignee: Atopic Pty. Ltd.Inventor: Thomas J. Borody
-
Patent number: 5519014Abstract: A medicine for treating non-inflammatory and non-infectious bowel disorders, such as irritable bowel syndrome, constipation, non-ulcer dyspepsia, gastro-oesophageal reflux with or without oesophagitis, and diverticular disease, comprising a salicylic acid derivative, such as any one of sulfasalazine, 5-aminosalicylic acid, 4-aminosalicylic acid, and benzalazine, or a combination of any two or more thereof. The treatment of those disorders comprises taking the medicine by mouth to provide a dosage rate of the salicylic acid derivative of from 200 mg to 18 g per day.Type: GrantFiled: June 17, 1994Date of Patent: May 21, 1996Inventor: Thomas J. Borody
-
Patent number: 5476669Abstract: A method is disclosed for preventing the recurrence of duodenal ulcer associated with Campylobacter pylori (Helicobacter pylori) infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound, a first antibiotic selected from the group consisting of tetracycline and penicillins, and a second antibiotic which is metronidazole.Type: GrantFiled: August 31, 1992Date of Patent: December 19, 1995Assignees: Examed Australia Pty. Ltd., Ostapat Pty. Limited, Gastro Services Pty. Limited, Capability Services Pty. LimitedInventor: Thomas J. Borody
-
Patent number: 5443826Abstract: A method of treating chronic disorders associated with the presence of abnormal microflora or an abnormal distribution of microflora in the gastrointestinal tract. The method involves the removal of at least a portion of the host's existing enteric microflora and the substitution of an effective amount of predetermined microflora. Pharmaceutical compositions which comprise viable microorganisms in a composition resembling the host's normal healthy faecal flora are also disclosed.Type: GrantFiled: August 6, 1993Date of Patent: August 22, 1995Inventor: Thomas J. Borody
-
Patent number: 5274001Abstract: The present invention relates to orthostatic lavage solutions or colon evacuants for cleansing the gastrointestinal tract, or for treatment of bowel diseases and/or disorders, containing an effective amount of ascorbic acid or a salt thereof.Type: GrantFiled: July 17, 1990Date of Patent: December 28, 1993Inventor: Thomas J. Borody
-
Patent number: 5273032Abstract: An endoscopic mouth guard having a smoothly contoured, waisted tube merging into a peripheral flange at the front end of said tube, a manifold integral with the front face of said flange defining a closed ended, transverse distribution duct, and two open ended, upwardly directed branch ducts ending, in use, closely below the nostrils of a patient fitted with the guard, two further, open ended branch ducts extending rearwardly from said distributor duct into the bore of said tube, and a laterally and rearwardly directed tapered spigot on said manifold, defining an extension of said distributor duct, adapted to enter the bore of a gas supply tube. The finished guard is a single article of plastics material having a smooth hard surface.Type: GrantFiled: May 29, 1992Date of Patent: December 28, 1993Assignee: Gastro Services Pty Ltd.Inventor: Thomas J. Borody
-
Patent number: 5196205Abstract: A method is disclosed for preventing recurrence of duodenal ulcer associated with Campylobacter pylori infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound; a first antibiotic selected from the group consisting of tetracycline and penicillins and second antibiotic which is metronidazole.Type: GrantFiled: June 12, 1990Date of Patent: March 23, 1993Inventor: Thomas J. Borody